

Dimensional advantage: How 3D organoids are re-shaping the oncology research



Submission: 03-02-2024

Revision: 08-02-2024

Publication: 01-03-2024

Traditional *in vitro* 2D cell culture-based models have limitations in cancer research, as they do not accurately reflect the complex 3D architecture and interactions we find in tumors. Cell–cell communications are vital for cancer growth and proliferation.¹ Cancer cells communicate with each other and surrounding cells through various pathways, sending signals that promote their growth, survival, and proliferation through autocrine, paracrine, and endocrine.² Fundamentally, this communication forms the basis of cancer survival.³ This can involve growth factors, cytokines, and other molecules that activate essential signaling pathways for tumor growth.⁴ Cancer cells need constant blood and nutrients to sustain such massive growth. This is again achieved by communication with endothelial cells to stimulate the formation of new blood vessels to sustain their energy and metabolic needs.⁵ Conventional 2D and 3D cultures play a role in oncology research, but each has its strengths and weaknesses when it comes to studying cancer.⁶ While 2D culture systems are simple, easier, and inexpensive to set up and maintain, 3D cultures are more realistic representations of actual tumors due to their 3D structure and cell–cell interactions.⁷ They can capture the genetic and functional heterogeneity of patient-derived tumors, thereby allowing for modeling the tumor microenvironment with various cell types and signaling and immune molecules.⁸ 2D culture fails to accurately reflect the complex 3D architecture and interactions of cells as seen *in vivo* due to their limited ability to model cell–cell interactions and the tumor microenvironment.⁹ 3D culture-derived organoids behave like miniature, simplified organs *in vitro*, which can be used for drug testing, disease modeling, and regenerative medicine applications.^{10,11} By creating conditions mimicking embryonic development, 3D culture can be used to study organogenesis and tissue morphogenesis. 3D culture models can also be used to study the interaction between pathogens and host cells, providing a more accurate representation of *in vivo* conditions than traditional 2D cultures.^{12,13}

Therefore, the use of 3D culture is multidimensional and spans multiple avenues, contributing to our advancements in understanding biology, disease mechanisms, oncology research, and the development of novel therapeutic strategies.^{14,15}

Access this article online

Website:

<http://nepjol.info/index.php/AJMS>

DOI: 10.3126/ajms.v15i3.62513

E-ISSN: 2091-0576

P-ISSN: 2467-9100

Copyright (c) 2024 Asian Journal of Medical Sciences



This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Ruby Dhar¹, Arun Kumar², Subhradip Karmakar³

¹Scientist, Room 3020, Department of Biochemistry, ³Additional Professor, Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, ²Professor, Department of Biochemistry, Narayan Medical College, Gopal Narayan Singh University, Sasaram, Bihar, India

Address for Correspondence:

Dr. Subhradip Karmakar, Additional Professor, Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India. **Mobile:** +91-9999612564. **E-mail:** subhradipaiims@gmail.com

Dr. Arun Kumar, Professor, Department of Biochemistry, Narayan Medical College, Gopal Narayan Singh University, Sasaram, Bihar, India. **Mobile:** +91-7584089886. **E-mail:** profdrarunk@gnsu.ac.in

REFERENCES

1. Mesnil M and Yamasaki H. Cell-cell communication and growth control of normal and cancer cells: Evidence and hypothesis. *Mol Carcinog.* 1993;7(1):14-17. <https://doi.org/10.1002/mc.2940070103>
2. Reyna-Jeldes M, Díaz-Muñoz M, Madariaga JA, Coddou C and Vázquez-Cuevas FG. Autocrine and paracrine purinergic signaling in the most lethal types of cancer. *Purinergic Signal.* 2021;17(3):345-370. <https://doi.org/10.1007/s11302-021-09785-8>
3. Bonacquisti EE and Nguyen J. Connexin 43 (Cx43) in cancer: Implications for therapeutic approaches via gap junctions. *Cancer Lett.* 2019;442:439-444. <https://doi.org/10.1016/j.canlet.2018.10.043>

4. Fantuzzi G. Cancer is a propagandist. *Stud Hist Philos Biol Biomed Sci.* 2017;63:28-31.
<https://doi.org/10.1016/j.shpsc.2017.04.001>
5. Sahoo OS, Pethusamy K, Srivastava TP, Talukdar J, Alqahtani MS, Abbas M, et al. The metabolic addiction of cancer stem cells. *Front Oncol.* 2022;12:955892.
<https://doi.org/10.3389/fonc.2022.955892>
6. Habanjar O, Diab-Assaf M, Caldefie-Chezet F and Delort L. 3D cell culture systems: Tumor application, advantages, and disadvantages. *Int J Mol Sci.* 2021;22(22):12200.
<https://doi.org/10.3390/ijms222212200>
7. Atat OE, Farzaneh Z, Pourhamzeh M, Taki F, Abi-Habib R, Vosough M, et al. 3D modeling in cancer studies. *Hum Cell.* 2022;35(1):23-36.
<https://doi.org/10.1007/s13577-021-00642-9>
8. Suarez-Martinez E, Suazo-Sanchez I, Celis-Romero M and Camero A. 3D and organoid culture in research: physiology, hereditary genetic diseases and cancer. *Cell Biosci.* 2022;12(1):39.
<https://doi.org/10.1186/s13578-022-00775-w>
9. Kapalczyńska M, Kolenda T, Przybyła W, Zajączkowska M, Teresiak A, Filas V, et al. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. *Arch Med Sci.* 2018;14(4):910-919.
<https://doi.org/10.5114/aoms.2016.63743>
10. Drost J and Clevers H. Organoids in cancer research. *Nat Rev Cancer.* 2018;18(7):407-418.
<https://doi.org/10.1038/s41568-018-0007-6>
11. Qu J, Kalyani FS, Liu L, Cheng T and Chen L. Tumor organoids: Synergistic applications, current challenges, and future prospects in cancer therapy. *Cancer Commun (Lond).* 2021;41(12):1331-1353.
<https://doi.org/10.1002/cac2.12224>
12. Wood LD and Ewald AJ. Organoids in cancer research: A review for pathologist-scientists. *J Pathol.* 2021;254(4):395-404.
<https://doi.org/10.1002/path.5684>
13. Devarasetty M, Mazzocchi AR and Skardal A. Applications of bioengineered 3D tissue and tumor organoids in drug development and precision medicine: Current and future. *BioDrugs.* 2018;32(1):53-68.
<https://doi.org/10.1007/s40259-017-0258-x>
14. Xu R, Zhou X, Wang S and Trinkle C. Tumor organoid models in precision medicine and investigating cancer-stromal interactions. *Pharmacol Ther.* 2021;218:107668.
<https://doi.org/10.1016/j.pharmthera.2020.107668>
15. Yang L, Yang S, Li X, Li B, Li Y, Zhang X, et al. Tumor organoids: From inception to future in cancer research. *Cancer Lett.* 2019;454:120-133.
<https://doi.org/10.1016/j.canlet.2019.04.005>

Authors Contribution:

RD, AK, and SK- Contributed equally toward the scripting of this editorial.

Work attributed to:

Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India and Department of Biochemistry, Narayan Medical College, Gopal Narayan Singh University, Sasaram, Bihar, India.

Orcid ID:

Dr. Ruby Dhar - <https://orcid.org/0000-0003-3600-6554>

Dr. Arun Kumar - <https://orcid.org/0000-0002-8800-0296>

Dr. Subhradip Karmakar - <https://orcid.org/0000-0002-4757-8729>

Source of Support: Nil, **Conflicts of Interest:** None declared.